Form 4: Protara Therapeutics VP Controller Sells Shares for Tax Obligations

Protara Therapeutics' VP, Controller, Hannah Fry, disposed of 2,132 common shares to cover tax liabilities from vested restricted stock units.

Summary

• Hannah Fry, the VP, Controller of Protara Therapeutics, Inc. (TARA), reported a transaction on January 20, 2026.
• The transaction involved the disposition of 2,132 shares of Protara Therapeutics common stock.
• These shares were withheld by the Issuer to satisfy income tax obligations.
• The tax obligations are associated with the vesting of Restricted Stock Unit (RSU) Awards granted to Ms. Fry on January 19, 2023, and January 19, 2024.
• The shares were disposed of at a price of $5.6 per share.
• Following this reported transaction, Ms. Fry beneficially owns 44,180 shares of common stock directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common part of executive compensation. It does not reflect a change in management's view of the company's prospects or operational performance.

Future Outlook

The filing, an SEC Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction where an executive sells shares to cover tax liabilities upon the vesting of restricted stock units. This is a common practice in executive compensation across various industries and does not typically reflect specific industry trends or competitive positioning.

Related Party Transactions

• The transaction involves an officer of the company disposing of shares to the issuer to satisfy tax obligations related to vested restricted stock units, which is a common compensation-related dealing between a company and its executives.

Stakeholder Impact

• No significant direct impact on shareholders, employees, customers, suppliers, or creditors is expected, as this is a routine, non-discretionary transaction related to executive compensation and not indicative of operational or strategic changes.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically indicate a change in the company's fundamentals or management's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Protara Therapeutics, TARA, Form 4, Insider Transaction, Hannah Fry, Restricted Stock Units, Tax Withholding, Common Stock, Beneficial Ownership